WEBULL
News
PSNL
7.93
+2.39%
0.19
Personalis Announced The Publication Of A New Study In A Journal Of The American Association For Cancer Research, Providing Clinical Evidence That The Company's NeXT Personal, Can Effectively Predict Patient Outcomes Across Various Cancers And Immunotherapy Modalities
Benzinga · 1d ago
Personalis Study Shows Ultrasensitive ctDNA Test Predicts Immunotherapy Outcomes Across Solid Tumors
Reuters · 1d ago
PERSONALIS ANNOUNCES NEW PUBLICATION APPLYING ULTRASENSITIVE CTDNA TESTING TO MONITORING CANCER IMMUNOTHERAPY RESPONSE ACROSS SOLID TUMORS
Reuters · 1d ago
Weekly Report: what happened at PSNL last week (1208-1212)?
Weekly Report · 3d ago
Personalis Publishes Landmark TRACERx Study Showing NeXT Personal Test Detects Lung Cancer Relapse Months Ahead Of Imaging
Benzinga · 12/11 14:08
Personalis NeXT Personal Test Shows High Sensitivity for Lung Cancer MRD Detection in Landmark Study
Reuters · 12/11 14:00
Weekly Report: what happened at PSNL last week (1201-1205)?
Weekly Report · 12/08 10:24
Personalis assumed with an Equal Weight at Morgan Stanley
TipRanks · 12/01 21:35
Analysts Offer Insights on Healthcare Companies: Personalis (PSNL), Dyadic International (DYAI) and NeurAxis, Inc. (NRXS)
TipRanks · 12/01 13:30
Weekly Report: what happened at PSNL last week (1124-1128)?
Weekly Report · 12/01 10:19
Personalis Announces $100M Stock Offering Amendment
TipRanks · 11/28 22:48
Personalis CFO and COO Aaron Tachibana Reports Disposal of Common Shares
Reuters · 11/28 22:10
Personalis: A Growth Inflection Is Imminent, Hold
Seeking Alpha · 11/28 03:34
Personalis (PSNL) Gets a Buy from Lake Street
TipRanks · 11/25 13:55
Personalis Sees Revised Reimbursement Rates for Cancer Tests
TipRanks · 11/25 11:27
PERSONALIS INC - EFFECTIVE DECEMBER 1, REIMBURSEMENT RATE FOR NEXT PERSONAL DX BREAST MRD TEST SET AT $4,266 - SEC FILING
Reuters · 11/25 11:14
Weekly Report: what happened at PSNL last week (1117-1121)?
Weekly Report · 11/24 10:24
Personalis Inc. to Attend Piper Sandler 37th Annual Healthcare Conference
Reuters · 11/18 21:01
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
Barchart · 11/18 15:01
Weekly Report: what happened at PSNL last week (1110-1114)?
Weekly Report · 11/17 10:24
More
Webull provides a variety of real-time PSNL stock news. You can receive the latest news about Personalis through multiple platforms. This information may help you make smarter investment decisions.
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.